BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study
Expanded Access Protocol for CaspaCIDe T Cells From An HLA-Partially Matched Related Donor After Negative Selection of TCR αβ+T Cells In Pediatric Patients Affected by Hematological and Other Disorders
Sponsor: Bellicum Pharmaceuticals
A observational or N/A phase clinical study on Hurler Syndrome and Inborn Errors of Metabolism, this trial is ongoing. The trial is conducted by Bellicum Pharmaceuticals and has accumulated 8 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Jan 2021 — Jul 2024 [monthly]
No Longer Available
-
Nov 2020 — Jan 2021 [monthly]
No Longer Available
-
Feb 2020 — Nov 2020 [monthly]
No Longer Available
Status: Available → No Longer Available
▶ Show 3 earlier versions
-
Nov 2019 — Feb 2020 [monthly]
Available
-
Nov 2018 — Nov 2019 [monthly]
Available
-
Sep 2018 — Nov 2018 [monthly]
Available
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bellicum Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .